Back
Full-text
Journal article

Intralymphatic Immunotherapy: Update and Unmet Needs.

  • Senti G Clinical Trials Center, University Hospital Zurich, Zurich, Switzerland, gabriela.senti@usz.ch.
  • Freiburghaus AU Clinical Trials Center, University Hospital Zurich, Zurich, Switzerland.
  • Larenas-Linnemann D Hospital Médica Sur, Mexico City, Mexico.
  • Hoffmann HJ Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Patterson AM ENT & Allergy Specialists of Northwest Ohio, Findlay, Ohio, USA.
  • Klimek L Center for Rhinology and Allergology, Wiesbaden, Germany.
  • Di Bona D Department of Emergency and Organ Transplantation, Chair and School of Allergology and Clinical Immunology, University of Bari - Aldo Moro, Bari, Italy.
  • Pfaar O Center for Rhinology and Allergology, Wiesbaden, Germany.
  • Ahlbeck L Department of Clinical and Experimental Medicine, Division of Neuro and Inflammation Sciences, Linköping University, Linköping, Sweden.
  • Akdis M Swiss Institute of Allergy and Asthma Research SIAF, Davos Platz, Switzerland.
  • Weinfeld D Asthma and Allergy Clinic (Adults), Department of Internal Medicine, South Alvsborgs (Central) Hospital, Boras, Sweden.
  • Contreras-Verduzco FA Allergy Department, National Institute of Pediatrics, Mexico City, Mexico.
  • Pedroza-Melendez A Allergy Department, National Institute of Pediatrics, Mexico City, Mexico.
  • Skaarup SH Department of Clinical Medicine - Department of Respiratory Diseases and Allergy, Aarhus University, Aarhus, Denmark.
  • Lee SM Division of Allergy and Pulmonology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea.
  • Cardell LO Division of ENT Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
  • Schmid JM Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark.
  • Westin U Division of Ear, Nose and Throat Diseases, Head and Neck Surgery, Department of Clinical Sciences, Lund University, Skane University Hospital, Lund, Sweden.
  • Dollner R Department Otorhinolaryngology - Head and Neck Surgery, Clinic for Head-Neck and Reconstructive Surgery, Oslo University Hospital (OUS) HF - Rikshospitalet, Oslo, Norway.
  • Kündig TM Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
Show more…
  • 2018-11-05
Published in:
  • International archives of allergy and immunology. - 2019
Allergen-specific immunotherapy
Allergy
Clinical trials
Intralymphatic immunotherapy
Allergens
Clinical Trials as Topic
Desensitization, Immunologic
Humans
Hypersensitivity
Injections, Subcutaneous
Lymph Nodes
Sublingual Immunotherapy
Treatment Outcome
English Allergen-specific immunotherapy (AIT) is the only allergy treatment that confers long-term symptom amelioration for patients suffering from allergy. The most frequently used allergen application route is subcutaneous injection (SCIT), commonly taken as the gold standard, followed by sublingual (SLIT) or oral (OIT) application of allergen preparations. This is an up-to-date review of the clinical evidence for a novel route of allergen application, i.e., directly into lymph nodes - intralymphatic immunotherapy (ILIT). The major advantages of ILIT over the current AIT approaches are its short duration and the low allergen doses administered. The whole treatment consists of merely 3 ultrasound-guided injections into inguinal lymph nodes 1 month apart. While the number of patients included in randomised controlled trials is still limited, the clinical results for ILIT are encouraging, but more clinical trials are needed, as well as more preclinical work for optimising formulations.
Language
  • English
Open access status
bronze
Identifiers
Persistent URL
https://sonar.ch/global/documents/3696
Statistics
Document views: 51 File downloads:
  • Full-text: 0